Celtic Pharma Announces Successful Completion of Phase I/II study of Xerecept® in Pediatric Patients with Cerebral Tumors - Business Wire

“It is exciting to observe the ability of Xerecept® to be associated with dexamethasone dosing reduction in pediatric patients. In this study, all of the key stakeholders including patients, parents and investigators were impressed with the study ...

Altitude Sickness Claims Lives On Mount Everest Expedition: What Is It? - Huffington Post

A drug called acetazolamide, or Diamox, could also help with breathing, while a drug called dexamethasone, or Decadron, can help to reduce brain swelling, according to the National Institutes of Health. To prevent altitude sickness, the NIH ...

Celgene announces three phase III Revlimid trials in newly diagnosed MM patients - pharmabiz.com

Revlimid is not approved for use in newly diagnosed multiple myeloma. Revlimid is approved in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in nearly 70 countries ...

New England Journal of Medicine Reports on Three Phase III REVLIMID(R) (lenalidomide) Trials in Patients with Newly Diagnosed Multiple Myeloma - Marketwatch

REVLIMID is approved in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in nearly 70 countries, encompassing Europe, the Americas, the Middle-East and Asia ...

FDA Drug Safety Communication: Safety review update of cancer drug Revlimid (lenalidomide) and risk of developing new types of malignancies - Phramalive.com

These were multicenter, double-blind, placebo-controlled, parallel-group trials of Revlimid plus high-dose dexamethasone therapy versus dexamethasone alone in the treatment of patients with relapsed or refractory multiple myeloma. The incidence rates of ...

Onyx Pharmaceuticals Announces Data Presentations at 48th American Society of Clinical Oncology Annual Meeting - Yahoo Finance

Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) Dr. Andrzej J. Jakubowiak, University of Chicago, United States Sunday ...

Mometasone Furoate Cream, or the way you can now effortlessly treat ev - 1UP.COM

Quite the opposite, like a steroid it's much less potent than dexamethasone. Consequently, general it is actually regarded as being a synthetic medium-potency corticosteroid. Memotasone furoate cream formations are for external use only. Mometasone furoate ...

TAKEDA PHARMA : Millennium and Takeda Announce Presentations for Key Investigational Molecules at American Society of Clinical Oncology Annual Meeting - 4-traders (press release)

MLN9708 Data Key presentations will include: Oral weekly MLN9708, an investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma (MM): a phase 1/2 study Presenter ...

Olanzapine Reduces Breakthrough Chemo-Induced Emesis - Medscape News

CINV prophylaxis included dexamethasone (12 mg intravenously [IV]), palonosetron (0.25 mg IV), and fosaprepitant (150 mg IV) prior to chemotherapy, and dexamethasone (8 mg orally daily on days 2 to 4) after chemotherapy. Patients who developed ...